A detailed history of Rhumbline Advisers transactions in Connect Biopharma Holdings LTD stock. As of the latest transaction made, Rhumbline Advisers holds 9,500 shares of CNTB stock, worth $9,215. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,500
Previous 9,500 -0.0%
Holding current value
$9,215
Previous $14,000 7.14%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$1.28 - $2.2 $8,985 - $15,444
-7,020 Reduced 42.49%
9,500 $14,000
Q3 2023

Nov 09, 2023

BUY
$0.65 - $1.18 $4,280 - $7,770
6,585 Added 66.28%
16,520 $13,000
Q2 2023

Aug 08, 2023

BUY
$1.01 - $1.25 $10,034 - $12,418
9,935 New
9,935 $11,000

Others Institutions Holding CNTB

About Connect Biopharma Holdings Ltd


  • Ticker CNTB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,015,800
  • Market Cap $53.4M
  • Description
  • Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for t...
More about CNTB
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.